American Well Corporation (AMWL) Q3 2025 Earnings Call Transcript

American Well Corporation ( AMWL ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Ido Schoenberg - Chairman & CEO Mark Hirschhorn - Executive VP, COO & CFO Conference Call Participants Stanislav Berenshteyn - Wells Fargo Securities, LLC, Research Division Charles Rhyee - TD Cowen, Research Division Jenny Cao - Truist Securities, Inc., Research Division Jack Senft - UBS Investment Bank, Research Division John Park - Morgan Stanley, Research Division Presentation Operator " Ido Schoenberg Chairman & CEO " Mark Hirschhorn Executive VP, COO & CFO " Stanislav Berenshteyn Wells Fargo Securities, LLC, Research Division " Wells Fargo Securities, LLC, Research Division Charles Rhyee TD Cowen, Research Division " TD Cowen, Research Division Jenny Cao Truist Securities, Inc., Research Division " Truist Securities, Inc., Research Division Jack Senft UBS Investment Bank, Research Division " UBS Investment Bank, Research Division John Park Morgan Stanley, Research Division " Morgan Stanley, Research Division Operator Hello, everyone, and welcome to Amwell's conference call to discuss their third fiscal quarter of 2025. Joining us on the call today are Amwell's Chairman and CEO, Dr. Ido Schoenberg; and Mark Hirschhorn, Amwell's CFO and Chief Operating Officer.

Seeking Alpha • Nov 5, 2025

Amwell® Announces Results for Third Quarter 2025

BOSTON , Nov. 04, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results for the third quarter ended September 30. The company's third quarter earnings report may be viewed at investors.amwell.com.

GlobeNewsWire • Nov 4, 2025

Compared to Estimates, American Well (AMWL) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for American Well (AMWL) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Nov 5, 2025

American Well Corporation (AMWL) Reports Q3 Loss, Beats Revenue Estimates

American Well Corporation (AMWL) came out with a quarterly loss of $1.74 per share versus the Zacks Consensus Estimate of a loss of $1.83. This compares to a loss of $2.87 per share a year ago.

Zacks Investment Research • Nov 5, 2025

Amwell® to report third quarter 2025 operating results; company leaders to attend upcoming investor conferences

BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report third quarter 2025 operating results after stock market trading hours on Tuesday, Nov. 4.

GlobeNewsWire • Oct 27, 2025

From Apps to Nutrition: Health & Fitness Stocks to Buy Now

UNFI, AMWL, STKL, and PTON stand out as health and fitness plays, tapping into booming demand for wellness, nutrition and digital care.

Zacks Investment Research • Oct 3, 2025

American Well Corporation (AMWL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

American Well Corporation (NYSE:AMWL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 2:35 PM EDT Company Participants Ido Schoenberg - Chairman & CEO Mark Hirschhorn - Executive VP, COO & CFO Conference Call Participants Craig Hettenbach - Morgan Stanley, Research Division Presentation Craig Hettenbach VP & Equity Analyst Good afternoon, everyone. I'm Craig Hettenbach.

Seeking Alpha • Sep 9, 2025

HIMS vs. AMWL: Which Stock Has the Stronger Global Growth Strategy?

Hims & Hers expands globally, while Amwell leans on federal contracts and software growth. Let's see which has the edge in earnings growth & strategic expansion.

Zacks Investment Research • Aug 28, 2025

American Well Q2 Review: Hold Rating Maintained Amid DHA Renewal Concerns

American Well's revenue growth and cost control are strong, but the short DHA contract extension raises concerns about long-term stability and reliability of key revenue streams. Amwell's shift to higher-margin software revenue is promising, but guidance was revised downward due to contract uncertainties and program exclusions. Cost reductions have improved EBITDA and cash flow outlook, but excessive cuts risk undermining R&D, marketing, and future growth potential.

Seeking Alpha • Aug 13, 2025

Amwell makes grant to new employees under inducement plan

BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Amwell ®  (NYSE: AMWL), a leading technology-enabled care platform provider, announces that on August 8, Amwell made grants of RSUs covering an aggregate of 76,198 shares of its Class A common stock to two new employees. The grants were offered as material inducement to the employees' employment with Amwell.

GlobeNewsWire • Aug 8, 2025